[go: up one dir, main page]

TR200003161T2 - Poliol-IFN-Beta konjugatları - Google Patents

Poliol-IFN-Beta konjugatları

Info

Publication number
TR200003161T2
TR200003161T2 TR2000/03161T TR200003161T TR200003161T2 TR 200003161 T2 TR200003161 T2 TR 200003161T2 TR 2000/03161 T TR2000/03161 T TR 2000/03161T TR 200003161 T TR200003161 T TR 200003161T TR 200003161 T2 TR200003161 T2 TR 200003161T2
Authority
TR
Turkey
Prior art keywords
ifn
polyol
peg
conjugates
beta conjugates
Prior art date
Application number
TR2000/03161T
Other languages
English (en)
Inventor
El Tayar Nabil
J. Roberts Michael
Harris Milton
Sawlivich Wayne
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of TR200003161T2 publication Critical patent/TR200003161T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PEG ünitesi, insan IFN- Cys17 ile kovalent bag yapan PEG-IFN- konjugatlari bir tiolreaktif PEGilasyon ajani kullanimi ile site spesifik PEGilasyon prosesi üzerinden üretilir. Enfeksiyon, tümör ve otoimün ve enflamatör hastaliklarin tedavi edilmesine yönelik bir farmakotik kompozisyon ve bir metot da temin edilir. Bu bulus, PEG ünitelerinin bir polipeptide ve daha özel anlamda IFN- 'ya seri sekilde, adim adim eklenmesi metodu ile de ilgilidir. (SEKIL 1)
TR2000/03161T 1998-04-28 1999-04-28 Poliol-IFN-Beta konjugatları TR200003161T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8333998P 1998-04-28 1998-04-28

Publications (1)

Publication Number Publication Date
TR200003161T2 true TR200003161T2 (tr) 2001-01-22

Family

ID=22177687

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2000/03161T TR200003161T2 (tr) 1998-04-28 1999-04-28 Poliol-IFN-Beta konjugatları
TR2001/01751T TR200101751T2 (tr) 1998-04-28 1999-04-28 Poliol-IFN-beta konjugatları

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2001/01751T TR200101751T2 (tr) 1998-04-28 1999-04-28 Poliol-IFN-beta konjugatları

Country Status (30)

Country Link
US (3) US6638500B1 (tr)
EP (2) EP1075281B1 (tr)
JP (2) JP4574007B2 (tr)
KR (1) KR100622796B1 (tr)
CN (2) CN1187094C (tr)
AR (1) AR020070A1 (tr)
AT (2) ATE365563T1 (tr)
AU (1) AU762621B2 (tr)
BG (2) BG65046B1 (tr)
BR (1) BR9910023A (tr)
CA (2) CA2565375A1 (tr)
CY (1) CY1108022T1 (tr)
CZ (2) CZ298579B6 (tr)
DE (2) DE69936409T2 (tr)
DK (2) DK1421956T3 (tr)
EA (2) EA003789B1 (tr)
EE (1) EE05214B1 (tr)
ES (2) ES2224649T3 (tr)
HU (1) HUP0300548A3 (tr)
IL (1) IL139286A (tr)
NO (2) NO329749B1 (tr)
NZ (1) NZ507456A (tr)
PL (2) PL196533B1 (tr)
PT (2) PT1075281E (tr)
SI (2) SI1075281T1 (tr)
SK (2) SK286217B6 (tr)
TR (2) TR200003161T2 (tr)
TW (2) TWI232882B (tr)
UA (2) UA66857C2 (tr)
WO (1) WO1999055377A2 (tr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
EP2599503B1 (en) * 1998-10-16 2017-05-17 Biogen MA Inc. Polymer conjugates of interferon beta-1A and uses thereof
DK1121382T3 (da) * 1998-10-16 2006-11-13 Biogen Idec Inc Interferon-beta-fusionsproteiner og deres anvendelser
US6365179B1 (en) * 1999-04-23 2002-04-02 Alza Corporation Conjugate having a cleavable linkage for use in a liposome
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7431921B2 (en) 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
TR200101086A3 (tr) * 1999-10-15 2001-08-21
ATE522563T1 (de) 1999-12-24 2011-09-15 Kyowa Hakko Kirin Co Ltd Verzweigte polyalkylenglykole
HUP0203751A3 (en) 2000-01-10 2005-01-28 Maxygen Holdings Ltd Redwood C G-csf conjugates
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
EP1400550B1 (en) * 2001-01-30 2010-06-23 Kyowa Hakko Kirin Co., Ltd. Branched polyalkylene glycols
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
MXPA03007619A (es) 2001-02-27 2003-12-04 Maxygen Aps Nuevas moleculas similares a interferon beta.
JP4444652B2 (ja) 2001-07-11 2010-03-31 マキシゲン・ホールディングズ・リミテッド Ｇ−ｃｓｆ結合体
SK3102004A3 (sk) 2002-01-18 2005-01-03 Biogen Idec MA Inc. Polyalkylénglykol s časťou na konjugáciu biologicky aktívnej zlúčeniny
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
JP2006519170A (ja) * 2002-12-26 2006-08-24 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド サイトカイン、ケモカイン、増殖因子、ポリペプチドホルモン、およびレセプター結合活性が保存されたそのアンタゴニストのポリマー結合体
MXPA05006944A (es) 2002-12-26 2005-12-14 Mountain View Pharmaceuticals Conjugados polimericos de interferon-beta cion potencia biologica aumentada.
JP4847856B2 (ja) 2003-03-20 2011-12-28 バイエル ヘルスケア エルエルシー ＦＶＩＩおよびＦＶＩＩａの変種
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
EP2633866A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
NZ548255A (en) * 2004-02-02 2010-10-29 Ambrx Inc Modified human interferon polypeptides and their uses
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
WO2005110466A1 (en) 2004-05-17 2005-11-24 Ares Trading S.A. Hydrogel interferon formulations
AU2005249233B2 (en) 2004-06-01 2010-10-07 Ares Trading S.A. Stabilized interferon liquid formulations
JP2008500995A (ja) 2004-06-01 2008-01-17 アレス トレーディング ソシエテ アノニム タンパク質安定化法
AU2009212311B8 (en) 2004-07-21 2013-05-30 Ambrx, Inc. Modified leptin polypeptides and their uses
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
ATE494012T1 (de) † 2004-12-21 2011-01-15 Nektar Therapeutics Stabilisierte polymer-thiol-reagenzien
JP2008525473A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 修飾されたヒト成長ホルモン
WO2006073846A2 (en) 2004-12-22 2006-07-13 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
NZ555386A (en) * 2004-12-22 2011-01-28 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
MX2008001706A (es) * 2005-08-04 2008-04-07 Nektar Therapeutics Al Corp Conjugados de una porcion g-csf y un polimero.
SI1917276T1 (en) 2005-08-26 2018-05-31 Ares Trading S.A. PROCEDURE FOR PREPARATION OF GLYCOSYLATED INTERFERONE BETA
EP1933860A2 (en) 2005-09-01 2008-06-25 Ares Trading S.A. Treatment of optic neuritis
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
EP2395099A3 (en) * 2006-05-02 2012-05-16 Allozyne, Inc. Amino acid substituted molecules
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
RU2008145084A (ru) 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
WO2007135172A2 (en) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
CN101675071B (zh) * 2007-05-02 2014-06-18 Ambrx公司 经修饰干扰素β多肽和其用途
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
ATE555812T1 (de) * 2007-12-20 2012-05-15 Merck Serono Sa Peg-interferon-beta-formulierungen
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
US20100112660A1 (en) * 2008-05-30 2010-05-06 Barofold, Inc. Method for Derivatization of Proteins Using Hydrostatic Pressure
US20110124614A1 (en) * 2008-10-25 2011-05-26 Halina Offner Methods And Compositions For The Treatment of Autoimmune Disorders
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
JP5914363B2 (ja) 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
EP3372617B1 (en) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
CN102971006A (zh) 2010-07-15 2013-03-13 诺沃—诺迪斯克有限公司 稳定的因子viii变体
CN103209992A (zh) 2010-09-15 2013-07-17 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
CN103228290A (zh) * 2011-02-18 2013-07-31 (株)斯坦帝尔 包含沉默信息调节因子1表达诱导物质的败血症或者败血性休克的预防或者治疗用组合物
WO2013004607A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
CN109134642A (zh) * 2011-10-01 2019-01-04 株式会社糖锁工学研究所 加成糖链的多肽及含有该多肽的医药组合物
CA3179537A1 (en) 2012-02-27 2013-09-06 Amunix Pharmaceuticals, Inc. Xten conjugate compositions and methods of making same
EP2821079A4 (en) 2012-02-29 2016-05-04 Toray Industries MEANS FOR SUPPRESSING BODY CAVITIES
MY171183A (en) 2013-03-29 2019-09-30 Glytech Inc Polypeptide glycosylated with sialylated sugar chain
WO2016013911A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 페길화된 인터페론 -베타 변이체
WO2016013697A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체
RS61128B1 (sr) 2014-08-19 2020-12-31 Biogen Ma Inc Postupak pegilacije
CN107530396B (zh) 2015-05-01 2022-08-26 雅利斯塔制药公司 用于治疗眼科疾病的脂联素拟肽
PE20180498A1 (es) * 2015-06-19 2018-03-09 Eisai Randd Man Co Ltd Inmunoglobulinas conjugadas en cys80
AU2016354030B2 (en) 2015-11-09 2022-09-15 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
MX2019012347A (es) * 2017-04-17 2020-01-15 Univ Colorado Regents Optimizacion de terapia de reemplazo enzimatico para el tratamiento de la homocistinuria.
BR112020010282A2 (pt) 2017-11-24 2020-11-17 Merck Patent Gmbh regime de cladribina para uso no tratamento de formas progressivas de esclerose múltipla
US20220118050A1 (en) 2019-01-28 2022-04-21 Toray Industries, Inc. Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof
WO2020158691A1 (ja) 2019-01-28 2020-08-06 東レ株式会社 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2524586B2 (ja) * 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5208344A (en) * 1987-07-31 1993-05-04 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
KR960705579A (ko) 1993-11-10 1996-11-08 에릭에스. 딕커 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
TW496870B (en) * 1994-03-31 2002-08-01 Amgen Inc Compositions methods for stimulating megakaryocyte growth and differentiation
ATE299892T1 (de) * 1994-05-18 2005-08-15 Nektar Therapeutics Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
KR0176625B1 (ko) 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
JP2001508783A (ja) * 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
DE69838552T2 (de) * 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates

Also Published As

Publication number Publication date
CZ298597B6 (cs) 2007-11-21
SI1075281T1 (en) 2005-02-28
AU762621B2 (en) 2003-07-03
IL139286A (en) 2005-12-18
WO1999055377A2 (en) 1999-11-04
PL193352B1 (pl) 2007-02-28
BG65046B1 (bg) 2007-01-31
US20070141620A1 (en) 2007-06-21
EE200000614A (et) 2002-04-15
EA003789B1 (ru) 2003-10-30
HUP0300548A3 (en) 2005-07-28
ES2224649T3 (es) 2005-03-01
CZ298579B6 (cs) 2007-11-14
PT1421956E (pt) 2007-07-13
AR020070A1 (es) 2002-04-10
UA79430C2 (en) 2007-06-25
DE69936409D1 (de) 2007-08-09
EP1421956A1 (en) 2004-05-26
HUP0300548A2 (hu) 2003-06-28
DE69920002T2 (de) 2005-09-22
CN1637020A (zh) 2005-07-13
CA2565375A1 (en) 1999-11-04
DE69936409T2 (de) 2008-04-17
NO329749B1 (no) 2010-12-13
JP2010184929A (ja) 2010-08-26
KR20010071158A (ko) 2001-07-28
EE05214B1 (et) 2009-10-15
EP1075281B1 (en) 2004-09-08
NZ507456A (en) 2003-10-31
EP1421956B1 (en) 2007-06-27
EA200300382A1 (ru) 2005-02-24
JP2002512983A (ja) 2002-05-08
DE69920002D1 (de) 2004-10-14
CA2330451A1 (en) 1999-11-04
HK1076115A1 (en) 2006-01-06
CN1302209A (zh) 2001-07-04
NO20005337L (no) 2000-12-28
PL196533B1 (pl) 2008-01-31
CY1108022T1 (el) 2013-09-04
UA66857C2 (uk) 2004-06-15
SK16222000A3 (sk) 2001-04-09
US6638500B1 (en) 2003-10-28
PT1075281E (pt) 2004-11-30
SK286654B6 (sk) 2009-03-05
TWI232882B (en) 2005-05-21
US7700314B2 (en) 2010-04-20
CN100335503C (zh) 2007-09-05
EP1075281A2 (en) 2001-02-14
ES2285286T3 (es) 2007-11-16
DK1075281T3 (da) 2005-01-03
EA005495B1 (ru) 2005-02-24
EA200001111A1 (ru) 2001-04-23
JP4574007B2 (ja) 2010-11-04
ATE365563T1 (de) 2007-07-15
CZ20003995A3 (en) 2001-06-13
WO1999055377A9 (en) 2000-03-02
BG104871A (en) 2001-07-31
US20040043002A1 (en) 2004-03-04
AU3767499A (en) 1999-11-16
SI1421956T1 (sl) 2007-10-31
BR9910023A (pt) 2000-12-26
BG109291A (en) 2006-04-28
IL139286A0 (en) 2001-11-25
DK1421956T3 (da) 2007-10-01
NO20005337D0 (no) 2000-10-23
NO20100324L (no) 2000-12-28
NO332224B1 (no) 2012-07-30
TR200101751T2 (tr) 2002-05-21
CN1187094C (zh) 2005-02-02
TWI266800B (en) 2006-11-21
WO1999055377A3 (en) 1999-12-29
ATE275422T1 (de) 2004-09-15
KR100622796B1 (ko) 2006-09-13
US7357925B2 (en) 2008-04-15
BG64694B1 (bg) 2005-12-30
PL344490A1 (en) 2001-11-05
HK1038194A1 (en) 2002-03-08
SK286217B6 (sk) 2008-05-06

Similar Documents

Publication Publication Date Title
TR200003161T2 (tr) Poliol-IFN-Beta konjugatları
TR200001615T2 (tr) Polietilen Glikol-Grf konjugatlarının yere-özel hazırlanması.
EP0423201A4 (en) Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
DK0851925T3 (da) Humane Væksthormonvarianter
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
TR200000015T2 (tr) Bileşikler ve metodlar
BR9915542A (pt) Conjugados de polìmero de interferon beta-1a e usos
DE69910216D1 (de) Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung
ATE383430T1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
TR199901971T2 (tr) Bir reseptöre baglanan peptidler ve bilesikler.
ATE332918T1 (de) Neoglycoproteine
ATE263579T1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
DK0973819T3 (da) Ikke-antigene forgrenede polymerkonjugater
IL185763A0 (en) Peptides that lower blood glucose levels
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
TR199901949T2 (tr) Lemfositik tümörler için çareler.
BR9712589A (pt) Conjugado, composição farmacéutica, processos para tratar cáncer de próstata, para tratar hiperplasia prostática benigna, e, para fazer uma composição farmacêutica.
DK1142905T3 (da) Hidtil ukendt depsipeptidforbindelse
ATE249243T1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
TWI266801B (en) Polyol-IFN-beta conjugates
DE59706692D1 (de) Konjugat, geeignet zur bindung von substanzen